Sorbitan Monopalmitate
CAS 26266-57-9
Sorbitan Monopalmitate (CAS 26266-57-9) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| SORBITAN MONOPALMITATE | 1363701 | SU | MTHSPL |
| sorbitan monopalmitate | 1363701 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sorbitan Monopalmitate used for in pharmaceutical contexts?
Sorbitan Monopalmitate (CAS 26266-57-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sorbitan Monopalmitate?
No adverse-event association or SIDER side-effect rows are rendered for Sorbitan Monopalmitate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sorbitan Monopalmitate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for SORBITAN PALMITATE with EU status "permitted".
What clinical phase is Sorbitan Monopalmitate in?
Sorbitan Monopalmitate is rendered with ChEMBL max phase 2.